Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash from Investing Activities (2017 - 2024)

Solid Biosciences' Cash from Investing Activities history spans 8 years, with the latest figure at $38.6 million for Q4 2024.

  • For Q4 2024, Cash from Investing Activities fell 14.86% year-over-year to $38.6 million; the TTM value through Dec 2024 reached -$16.1 million, down 266.02%, while the annual FY2024 figure was -$16.1 million, 266.02% down from the prior year.
  • Cash from Investing Activities for Q4 2024 was $38.6 million at Solid Biosciences, up from -$11.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $66.1 million in Q4 2022 and bottomed at -$72.5 million in Q3 2021.
  • The 5-year median for Cash from Investing Activities is -$47500.0 (2020), against an average of -$1.6 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 90537.5% in 2021 before it skyrocketed 107937.14% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$60000.0 in 2020, then soared by 50393.33% to $30.2 million in 2021, then surged by 119.05% to $66.1 million in 2022, then tumbled by 31.47% to $45.3 million in 2023, then dropped by 14.86% to $38.6 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Cash from Investing Activities are $38.6 million (Q4 2024), -$11.0 million (Q3 2024), and -$5.2 million (Q2 2024).